Clinical Scorecard: Update on the Glaucoma Drug Landscape
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Reduction of intraocular pressure (IOP) through pharmacology, laser therapy, surgery, and minimally invasive glaucoma surgery (MIGS). |
| Target Population | |
| Care Setting |
Key Highlights
- NCX 470 offers a dual mechanism of action, lowering IOP by approximately 9 mmHg through NO-related relaxation of the trabecular meshwork.
- QLS-101 lowers IOP by widening aqueous outflow channels, particularly in patients with normal tension glaucoma.
Guideline-Based Recommendations
Diagnosis
Management
- Initiate treatment with topical medications, considering new pharmacologic options.
- Educate patients on new therapies and assess adherence.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with primary open-angle glaucoma and ocular hypertension.
New therapies provide alternatives for patients who do not respond to traditional treatments.
Clinical Best Practices
- Educate patients about new treatment options and their mechanisms.
- Streamline the prescribing process by understanding insurance and pharmacy logistics.
- Encourage patient compliance through education and support, including navigating insurance hurdles.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.